Search

Your search keyword '"Riess, Jonathan W."' showing total 202 results

Search Constraints

Start Over You searched for: Author "Riess, Jonathan W." Remove constraint Author: "Riess, Jonathan W." Database Unpaywall Remove constraint Database: Unpaywall
202 results on '"Riess, Jonathan W."'

Search Results

1. FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002).

3. Brief Report: Impact of anti-cancer treatments on outcomes of COVID-19 in patients with thoracic cancers: a CCC19 registry analysis

4. Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC

7. Objective analysis and clinical significance of the spatial tumor infiltrating lymphocyte patterns in non-small cell lung cancer (NSCLC)

8. Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer

9. Supplementary Table S2 from Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)

10. Supplementary Table S3 from Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)

11. Data from Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)

12. Supplementary Table S2 from Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)

13. Supplementary Figure S1 from Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)

14. Supplementary Table S1 from Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)

15. Data from Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)

16. Supplementary Figure S1 from Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)

17. Supplementary Table S3 from Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)

18. Supplementary Table S1 from Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non–Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)

19. Author response: Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study

21. Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial

22. Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

23. Supplementary Figure S7 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

24. Supplementary Figure S2 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

25. Supplementary Figure S9 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

26. Data from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

27. Supplementary Figure S6 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

28. Supplementary Figure S1 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

29. Supplementary Figure S8 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

30. Supplementary Figure S2 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

31. Supplementary Figure S3 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

32. Supplementary Figure S4 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

33. Supplementary Figure S5 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

34. Supplementary Figure S3 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

35. Supplementary Figure S4 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

36. Supplementary Figure S6 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

37. Supplementary Figure S8 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

38. Supplementary Figure S2 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

39. Supplementary Figure S1 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

40. Supplementary Figure S10 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

41. Supplementary Figure S9 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

42. Supplementary Figure S7 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

43. Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042)

44. ROS1

45. Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC

46. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

47. Data from Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

48. Supplementary Figure S2 from A Drug Repositioning Approach Identifies Tricyclic Antidepressants as Inhibitors of Small Cell Lung Cancer and Other Neuroendocrine Tumors

49. Supplementary Figures 1-8 from Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

50. Supplementary Figures 1-8 from Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions

Catalog

Books, media, physical & digital resources